BeOne Medicines differentiates on clinical evidence and execution speed. Its flagship medicine BRUKINSA demonstrated superior progression-free survival versus ibrutinib in the head-to-head Phase 3 ALPINE trial in relapsed or refractory chronic lymphocytic leukemia, while an internally discovered pipeline spanning BTK, BCL2, and immunotherapy modalities feeds a development engine of more than 30 clinical programs.
The company pairs in-house manufacturing and research sites across North America, Europe, and Asia-Pacific with its own commercial organization covering more than 75 countries, reaching about 1.8 million patients. This globally integrated model, run by roughly 12,000 employees across six continents, enables rapid trial enrollment and market access execution.
BeOne Medicines enters the second half of the decade with accelerating momentum: second-quarter 2026 revenue reached a record $1.7 billion, up 30 percent year over year, driven by BRUKINSA growth, prompting the company to raise its full-year guidance.
Regulatory expansion continues to widen the commercial base, with the 2026 accelerated approval of BEQALZI opening a new hematology franchise and TEVIMBRA advancing in first-line gastroesophageal cancer. Coupled with balance-sheet moves such as the up to $950 million IMDELLTRA royalty sale and continued pipeline investment, the company is positioned to deepen its presence in the global oncology market.
